Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
Translational Health Science and Technology Institute, Faridabad, Haryana, India.
Nat Commun. 2022 Jun 15;13(1):3451. doi: 10.1038/s41467-022-31170-1.
Many adults in India have received at least one dose of COVID-19 vaccine with or without a prior history SARS-CoV-2 infection. However, there is limited information on the effect of prior immunity on antibody response upon vaccination in India. As immunization of individuals continues, we aimed to assess whether pre-existing antibodies are further boosted by a single dose of BBV152, an inactivated SARS-CoV-2 vaccine, and, if these antibodies can neutralize SARS-CoV-2 Delta and Omicron variants. Here we show that natural infection during the second wave in 2021 led to generation of neutralizing antibodies against other lineages of SARS-CoV-2 including the Omicron variant, albeit at a significantly lower level for the latter. A single dose of BBV152 boosted antibody titers against the Delta and the Omicron variants but the antibody levels remained low against the Omicron variant. Boosting of antibodies showed negative correlation with baseline neutralizing antibody titers.
许多印度成年人已经接种了至少一剂 COVID-19 疫苗,无论他们是否有 SARS-CoV-2 感染史。然而,关于先前免疫对印度疫苗接种后抗体反应的影响的信息有限。随着个人免疫接种的继续,我们旨在评估先前存在的抗体是否会被一剂 BBV152(一种灭活的 SARS-CoV-2 疫苗)进一步增强,并且,如果这些抗体可以中和 SARS-CoV-2 的 Delta 和 Omicron 变体。在这里,我们表明,2021 年第二波期间的自然感染导致针对包括 Omicron 变体在内的 SARS-CoV-2 的其他谱系产生了中和抗体,但后者的水平明显较低。一剂 BBV152 可提高针对 Delta 和 Omicron 变体的抗体滴度,但针对 Omicron 变体的抗体水平仍然较低。抗体的增强与基线中和抗体滴度呈负相关。